Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Alaunos Therapeutics Inc TCRT

Healthcare Biotechnology

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity... see more

Add To Watchlist

Recent & Breaking News (NDAQ:TCRT)

ZIOPHARM and Intrexon Announce Cooperative Research and Development Agreement with the National Cancer Institute Utilizing Sleeping Beauty System to Generate T cells Targeting Neoantigens

PR Newswire January 10, 2017

Exclusive: Ziopharm CEO Talks Partnerships, Balance Sheet And JPM Healthcare Conference Presentation

Benzinga.com January 9, 2017

ZIOPHARM to Present at the 35th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2017

Biotech Stocks Under Scanner -- Geron, Keryx Biopharma, Heat Biologics, and ZIOPHARM Oncology

PR Newswire December 1, 2016

Watch These 5 Huge Call Purchases In Tuesday Trade

Benzinga.com November 29, 2016

Mid-Day Market Update: Crude Oil Up Over 2%; PhaseRx Shares Spike Higher

Benzinga.com November 28, 2016

ZIOPHARM Announces Clinical Data On Brain Cancer Drug

Benzinga.com November 17, 2016

ZIOPHARM Announces Clinical Data on Ad-RTS-hIL-12 Demonstrates Survival Benefits in Patients with Recurrent Brain Cancer

GlobeNewswire November 17, 2016

Sleeping Beauty System Used to Co-express CAR with Membrane-Bound IL-15 to Enhance Persistence of CD19-Specific T Cells

GlobeNewswire November 15, 2016

ZIOPHARM to Present at the Jefferies 2016 London Healthcare Conference

GlobeNewswire November 10, 2016

ZIOPHARM Reports Third Quarter 2016 Financial Results and Provides Update on Recent Activities

GlobeNewswire November 9, 2016

ZIOPHARM Announces Four Presentations at the 2016 ASH Annual Meeting

GlobeNewswire November 3, 2016

Biotech Stocks Technical Reports -- Navidea Biopharma, ZIOPHARM Oncology, Intra-Cellular Therapies, and Cempra

PR Newswire October 20, 2016

ZIOPHARM Presents Data Demonstrating Activation of Anti-Tumor Immune Response Using Ad-RTS-hIL-12 in Patients with Advanced Breast Cancer

GlobeNewswire October 10, 2016

ZIOPHARM to Present at the Jefferies Gene Editing/Therapy Summit

GlobeNewswire October 5, 2016

Watch These 5 Huge Put Purchases In Friday Trade

Benzinga.com September 9, 2016

ZIOPHARM to Present at the 2016 Wells Fargo Healthcare Conference

GlobeNewswire August 31, 2016

Mid-Afternoon Market Update: Guess? Jumps On Earnings Beat; Signet Jewelers Shares Tumble

Benzinga.com August 25, 2016

ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities

GlobeNewswire August 9, 2016

First-In-Human Trials using Non-Viral Sleeping Beauty System to Express CD19-Specific CAR in T cells Published in Journal of Clinical Investigation

GlobeNewswire August 4, 2016